View Older Stories View More Recent Stories

Nov 16, 2023 09:00AM Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis
Nov 6, 2023 04:01PM HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS
Nov 6, 2023 07:31AM Halozyme Therapeutics (HALO), Acumen announce global collaboration for ENHANZE
Nov 6, 2023 07:30AM Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease
Oct 30, 2023 06:35PM Halozyme To Report Third Quarter 2023 Financial and Operating Results
Oct 19, 2023 07:15AM Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear
Oct 16, 2023 03:05PM Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunit
Oct 16, 2023 08:08AM Halozyme Therapeutics (HALO) Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery
Oct 16, 2023 08:00AM Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery
Aug 31, 2023 08:30AM Halozyme to Present at Upcoming Investor Conferences
Aug 29, 2023 05:27AM Halozyme Therapeutics (HALO) Announces Approval of Roche's Tecentriq Subcutaneous (SC) with ENHANZE in the UK
Aug 29, 2023 04:50AM Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain
Aug 8, 2023 04:01PM HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS
Jul 25, 2023 08:30AM Halozyme To Report Second Quarter 2023 Financial and Operating Results
Jul 17, 2023 05:53AM Halozyme Therapeutics (HALO) Reports Positive Topline Data from argenx's ADHERE Study of VYVGART
Jul 17, 2023 01:15AM Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
Jul 13, 2023 05:41AM Halozyme Therapeutics (HALO) Reports Positive Data from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS with ENHANZE
Jul 13, 2023 01:15AM Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis
Jun 20, 2023 06:30PM Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis
Jun 6, 2023 08:30AM Halozyme to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
May 9, 2023 04:01PM HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS
Apr 25, 2023 08:30AM Halozyme To Report First Quarter 2023 Financial and Operating Results
Mar 15, 2023 07:45AM Halozyme Therapeutics (HALO) Provides Update On Licensee Co-formulation Patent Hearing In Europe
Mar 15, 2023 07:44AM HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
Feb 21, 2023 04:01PM HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS
Nov 22, 2022 03:05AM Halo Collective Reports Highest Selling Quarter for Budega Retail Locations and Plans to Continue Expansion
Nov 8, 2022 04:01PM HALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING RESULTS
Sep 22, 2022 05:00PM Halo Collective Completes Acquisition of Premium Indoor Grow and Distribution Hub in Portland, Oregon
Aug 16, 2022 08:00AM /R E P E A T -- Halo Collective Reports Second Quarter 2022 Financial Results/
Aug 16, 2022 02:00AM Halo Collective Reports Second Quarter 2022 Financial Results
Aug 12, 2022 08:00AM /R E P E A T -- Halo Collective Appoints Katie Field as Chairman of the Board/
Aug 12, 2022 02:14AM Halo Collective Appoints Katie Field as Chairman of the Board
Aug 10, 2022 04:15PM Halo Collective Receives All Regulatory Approvals for its Third Budega™ Dispensary in Hollywood, Halo's first Superstore
Aug 9, 2022 04:01PM HALOZYME REPORTS SECOND QUARTER 2022 FINANCIAL AND OPERATING RESULTS
Aug 8, 2022 04:45PM Halo Collective Announces Initiatives to Enhance Shareholder Value
Aug 2, 2022 05:54AM Halozyme Therapeutics (HALO) Reports Positive Results from Phase III IMscin001 Study
Aug 2, 2022 12:55AM Positive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq® with ENHANZE® in Advanced Non-Small Cell Lung Cancer
Jul 26, 2022 08:30AM Halozyme to Report Second Quarter 2022 Financial and Operating Results
Jul 1, 2022 04:15PM Halo Collective Promotes Katharyn Field to Chief Executive Officer
Jun 16, 2022 06:37PM Halo Announces Results of Annual General and Special Meeting
Jun 8, 2022 08:30AM Halozyme to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
Jun 7, 2022 08:30AM Halozyme Therapeutics (HALO) Announces Commercial Launch of TLANDO
Jun 7, 2022 08:30AM Halozyme Announces Commercial Launch of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy
May 24, 2022 08:30AM Halozyme Completes Antares Pharma Acquisition
May 21, 2022 03:16AM Halo Collective's BudegaTM Westwood Dispensary to Open May 27
May 21, 2022 03:16AM /C O R R E C T I O N from Source -- Halo Collective Inc./
May 18, 2022 07:05AM Halo Collective to Host Earnings Call Today at 4:15pm EST for First Quarter 2022 Financial Results
May 17, 2022 08:30AM /R E P E A T -- Halo Collective Reports First Quarter 2022 Financial Results; Book Value Per Share of $1.65 ($2.12 CAD)/
May 17, 2022 02:58AM Halo Collective Reports First Quarter 2022 Financial Results; Book Value Per Share of $1.65 ($2.12 CAD)
May 12, 2022 08:03AM Halozyme Therapeutics (HALO) Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of Antares Pharma (ATRS)
View More Recent Stories View Older Stories